[Thymogen in the complex treatment of inflammatory diseases of the female genital system].
Tsvelev. Iu V IuV; Khavinson. V Kh VKh; Diachuk. A V AV; Gur'ev. A V AV; Seryĭ. S V SV
Key Findings
- Thymogen combined with standard antibiotics normalized total lymphocyte, T‑cell, and B‑cell counts.
- T‑cell functional activity increased after treatment.
- No adverse reactions or desensitization effects were observed.
- Clinical symptoms of endomyometritis and related infections improved.
Practical Outcomes
- For biohackers interested in immune modulation, Thymogen appears safe and may boost certain immune parameters when added to conventional therapy for uterine infections. However, the lack of dosing details, control groups, and broader applicability means it’s not ready for a DIY protocol. More rigorous trials are needed before recommending it for general health or longevity use.
Summary
The study looked at 46 women with serious uterine infections and gave them a drug called Thymogen along with standard treatment. After the therapy, their immune cell numbers and activity improved, and no side effects were reported. The authors say Thymogen helped the patients get better, but the report doesn’t give details on dose, timing, or how it compares to a placebo.
Abstract
Thymogen, a new immunomodulating drug made in this country, was used in combined therapy of 46 patients with acute endomyometritis, exacerbations of chronic salpingo-oophoritis, purulent tubo-ovarian formations. Thymogen therapy was conducive to normalization of lymphocyte counts, absolute counts of T and B lymphocytes, increase of T lymphocyte functional activity. The drug is characterized by a desensitizing effect and induces no complications. Marked clinical effect recommends the immunomodulator thymogen for combined therapy of patients with inflammatory diseases of the uterus and its appendages.
Study Information
pubmed
1992